Structure-Activity Relationship Studies of β-Lactam-azide Analogues as Orally Active Antitumor Agents Targeting the Tubulin Colchicine Site

Dong-Jun Fu, Ling Fu, Ying-Chao Liu, Jun-Wei Wang, Yu-Qing Wang, Bing-Kai Han, Xiao-Rui Li, Chuang Zhang, Feng Li, Jian Song, Bing Zhao, Ruo-Wang Mao, Ruo-Han Zhao, Sai-Yang Zhang, Li Zhang, Yan-Bing Zhang & Hong-Min Liu

We have synthesized a series of new β-lactam-azide derivatives as orally active anti-tumor agents by targeting tubulin colchicine binding site and examined their structure activity relationship (SAR). Among them, compound 28 exhibited the most potent antiproliferative activity against MGC-803 cells with an IC$_{50}$ value of 0.106 μM by induction of G2/M arrest and apoptosis and inhibition of the epithelial to mesenchymal transition. 28 acted as a novel inhibitor of tubulin polymerization by its binding to the colchicine site. SAR analysis revealed that a hydrogen atom at the C-3 position of the β-lactam was required for the potent antiproliferative activity of β-lactam-azide derivatives. Oral administration of compound 28 also effectively inhibited MGC-803 xenograft tumor growth in vivo in nude mice without causing significant loss of body weight. These results suggested that compound 28 is a promising orally active anticancer agent with potential for development of further clinical applications.

Microtubules, filamentous cytoskeleton protein polymers composed of α- and β-tubulin heterodimers, are vital components of all cells and play diverse roles in a variety of essential cellular processes including maintenance of cell structure, protein trafficking, chromosomal segregation, and mitosis1–3. Microtubule targeting agents are known to interact with tubulin through at least four binding sites: the laulimalide site, paclitaxel site, vinblastine site, and colchicine site4. As one of the tubulin-targeting agents, colchicine binding site inhibitors exert their biological effects by inhibiting tubulin assembly and suppressing microtubule formation5–9. A water-soluble phosphate prodrug CA-4P targeting colchicine binding site has FDA-designated orphan drug status for the treatment of anaplastic thyroid cancer and ovarian cancer10. However, neural and cardiovascular toxicities of CA-4P currently represent the main obstacle to broad its clinical application in different cancers11. Therefore, there is still a need to develop new inhibitors of tubulin polymerization by targeting the colchicine binding site for cancer therapy.

β-Lactam skeleton has attracted much attention from medicinal chemists for many years because of their numerous biological activities12,13, especially their antitumor activity14–16. Apart from their pharmacological use, β-lactams have been used as synthons in the preparation of various heterocyclic compounds of biological significance17. For example, suitably substituted hydroxyl β-lactam has been used in the semisynthesis of a side chain bridged paclitaxel18. Importantly, some β-lactam analogues were shown to cause apoptosis in cancer cells through induction of microtubule disorganization and mitotic catastrophe19,20. Hence, in this study, β-lactam was chosen as a basic skeleton to develop new antitumor agents.

In addition, azide moiety has been widely used as a scaffold to design new chemical entities for anti-proliferation21–26 and arylazide derivatives have been shown to be potent antitumor agents. For example,
trans-2,3-dimethoxycinnamoyl azide derivative 1 (Fig. 1A) enhanced the in vitro and in vivo antitumor effect of romidepsin on bladder cancer cells. The Combretastatin A-4 aryl azide analogue 2 (Fig. 1A) displayed a potent anti-tubulin activity with an IC₅₀ value of 5.2 µM. 3′-(4-Azidophenyl)-3′-dephenylpaclitaxel 3 (Fig. 1A) was developed as a novel paclitaxel photoaffinity probe and shown to be as active as paclitaxel in tubulin assembly and cytotoxicity assays.

These intriguing findings and our continuous quest to identify more potent antitumor candidates led us to design novel β-lactam and azide hybrids. In this work, a series of β-lactam-azide derivatives as tubulin polymerization inhibitors were synthesized and evaluated their antitumor activity in vitro and in vivo. In addition, the detailed structure activity relationships in five regions of β-lactam-azides were explored (Fig. 1B) to provide further insight for developing more efficient tubulin targeting and antiproliferative agents for cancer therapy.

Results and Discussion

Chemistry. The synthetic routes of the desired novel β-lactam-azide derivatives were outlined in Fig. 2. Synthesis of β-lactams 12–28 was carried out using Staudinger reaction with in situ generation of a ketene and subsequent reaction with the appropriately substituted imines. The trans stereochemistry was observed for azetidin-2-one derivatives 12–28 with aromatic rings directly attached to positions 3 and 4 of the β-lactam scaffold, as evidenced by the coupling constants, J₃,4 ≈ 2.4 Hz. No cis isomers (J₃,4 ≈ 5 Hz) were detected in this series, possibly due to steric hindrance between the 3- and 4-positions of the β-lactam ring (Fig. 2A,B). To explore the effect of a large group or a long chain on the phenyl ring at the C-4 position of the β-lactam, 1,2,3-triazole analogues 29–32 in Fig. 2C as ring-closing products were synthesized through a Huisgen 1,3-dipolar cycloaddition. β-Lactams-triflones 35–36 were prepared via a Staudinger [2 + 2] cycladdition of imines with aryl trifly ketene generated in situ from 2-diazo-1-phenyl-2-(trifluoromethylsulfonyl) ethanone by a Wolff rearrangement in satisfactory to good yields from the reported procedure. An X-ray crystallography study of the β-lactam products was undertaken to confirm the stereochemical assignments and explore possible important structural features for potent activity. ORTEP diagram for compound 28 (CCDC number: 1526687) was presented.

Biology. Structure Activity Relationships. All synthesized β-lactam-azide derivatives were evaluated for their antiproliferative activity against three cancer cell lines (MGC-803, MCF-7, A549) using CCK-8 proliferation assay. The well-known anticancer drug CA-4P was used as a control. The results were summarized in Table 1.

In a series of analogues 12–25, we mainly investigated the effects of substitution on the phenyl ring at the C-3 position of the β-lactam (Region I), the importance of 3,4,5-trimethoxyphenyl group as the β-lactam N-1 substituent (Region II). During the SAR studies, we found that the substitution on the phenyl ring at the C-3 position of the β-lactam was important for the activity showing over 8-fold activity loss against the growth of MGC-803 cells, when the hydrogen atom was replaced with the methoxy group (18). β-Lactam-azide derivatives 12–16 and 21–22 without 3,4,5-trimethoxyphenyl group at the N-1 position of the β-lactam displayed relatively lower
Figure 2. Reagents and conditions: (a) NaNO₂, 2 M H₂SO₄, 0 °C, 30 min, NaN₃, rt, 2 h; (b) PCC, CH₂Cl₂, rt, 2 h; (c) EtOH, reflux; (d) substituted phenylacetyl chloride, triethylamine, anhydrous CH₂Cl₂, reflux, 3–8 h; (e) triethylamine, imines 8–9 or 11, anhydrous CH₂Cl₂, MgSO₄, reflux, 3–12 h; (f) CuSO₄.5H₂O, VcNa, THF-H₂O, rt, 12 h; (g) CF₃NaO₂S, DMAC, N₂, 50 °C, 14 h; (h) TfN₃, CH₃CN, pyridine, 0 °C, 16 h; (i) Substituted imine, toluene, N₂, 100 °C, 2 h.

antiproliferative activity (IC₅₀ > 20 μM) toward three cancer cell lines, indicating that the 3,4,5-trimethoxyphenyl group at the N-1 position was crucial for their antiproliferative activity.
inhibitory activity of analogues where an azide group was replaced by a large group (1,2,3-triazole) or a long chain (1,2,3-triazole-dithiocarbamate), the scaffold is promising for drug discovery. To complete the SAR study, the effects of hydrogen atom and a large chain on the phenyl ring at the C-4 position of the \(\beta\)-lactam was unfavorable for antiproliferative activity. 

\[ \beta \]-lactam lines. 

at the C-4 position of the \(\beta\)-lactam displayed a significantly improved antiproliferative activity to the cancer cell lines. Interestingly, when the -N\(_3\) was moved to the para-position, gave the IC\(_{50}\) values of 0.154–4.203 \(\mu\)M toward three cancer cell lines. 

Furthermore, \(\beta\)-lactam-1,2,3-triazoles were synthesized to evaluate the importance of azide group and the effect of a large group or a long chain on the phenyl ring at the C-4 position of the \(\beta\)-lactam (Region IV). When an azide group was replaced by a large group (1,2,3-triazole) or a long chain (1,2,3-triazole-dithiocarbamate), the inhibitory activity of analogues was completely lost. Those results suggested that a large group or a long chain on the phenyl ring at the C-4 position of the \(\beta\)-lactam was unfavorable for antiproliferative activity.

Because trifluoromethanesulfonyl moiety was an active group in some anticancer agents, it was often used as a promising scaffold for drug discovery. To complete the SAR study, the effects of hydrogen atom and a large group (e.g., –SO\(_2\)CF\(_3\)) as the \(\beta\)-lactam C-3 substituent were investigated (Region V). Changing the hydrogen atom at the C-3 position of the \(\beta\)-lactam to the trifluoromethanesulfonyl group resulted in inactive compounds. Indicating that the hydrogen atom was critical for antiproliferative activity. The detailed structure–activity relationships of all the synthesized \(\beta\)-lactam-azide derivatives were summarized as Supplementary Fig. S2.

### Table 1. IC\(_{50}\) values (\(\mu\)M) of synthesized compounds. 

| Compd. | MGC-803 | MCF-7 | A549 |
|--------|----------|--------|------|
| 12     | 0.106±0.001 | 0.120±0.001 | 20   |
| 13     | 0.110±0.001 | 0.120±0.001 | 20   |
| 14     | 0.120±0.001 | 0.120±0.001 | 20   |
| 15     | 0.130±0.001 | 0.120±0.001 | 20   |
| 16     | 0.140±0.001 | 0.120±0.001 | 20   |
| 17     | 0.150±0.001 | 0.120±0.001 | 20   |
| 18     | 0.160±0.001 | 0.120±0.001 | 20   |
| 19     | 0.170±0.001 | 0.120±0.001 | 20   |
| 20     | 0.180±0.001 | 0.120±0.001 | 20   |
| 21     | 0.190±0.001 | 0.120±0.001 | 20   |
| 22     | 0.200±0.001 | 0.120±0.001 | 20   |
| 23     | 0.210±0.001 | 0.120±0.001 | 20   |
| 24     | 0.220±0.001 | 0.120±0.001 | 20   |
| 25     | 0.230±0.001 | 0.120±0.001 | 20   |
| 26     | 0.240±0.001 | 0.120±0.001 | 20   |
| 27     | 0.250±0.001 | 0.120±0.001 | 20   |
| 28     | 0.260±0.001 | 0.120±0.001 | 20   |
| 29     | 0.270±0.001 | 0.120±0.001 | 20   |
| 30     | 0.280±0.001 | 0.120±0.001 | 20   |
| 31     | 0.290±0.001 | 0.120±0.001 | 20   |
| 32     | 0.300±0.001 | 0.120±0.001 | 20   |
| 33     | 0.310±0.001 | 0.120±0.001 | 20   |
| 34     | 0.320±0.001 | 0.120±0.001 | 20   |
| 35     | 0.330±0.001 | 0.120±0.001 | 20   |
| 36     | 0.340±0.001 | 0.120±0.001 | 20   |
| CA-4P  | 0.015±0.001 | 0.023±0.002 | 0.033±0.007 |

To investigate whether the heterocycle displayed an effect on the antiproliferative activity (Region I), compounds with a thiofuran ring (26–28) at the C-3 position of the \(\beta\)-lactam were synthesized. Replacing the phenyl scaffold at the C-3 position of the \(\beta\)-lactam with a thiofuran ring led to an increased activity (compound 25 vs. 28), indicating the importance of thiofuran at the C-3 position of \(\beta\)-lactam for their antiproliferative activity. We also explored the relationship between the location of azide group and their antiproliferative activity (Region III). Compound 26, which contained -N\(_3\) at the para-position, gave the IC\(_{50}\) values of 0.154–4.203 \(\mu\)M toward three cancer cell lines. 

Furthermore, \(\beta\)-lactam-1,2,3-triazoles were synthesized to evaluate the importance of azide group and the effect of a large group or a long chain on the phenyl ring at the C-4 position of the \(\beta\)-lactam (Region IV). When an azide group was replaced by a large group (1,2,3-triazole) or a long chain (1,2,3-triazole-dithiocarbamate), the inhibitory activity of analogues was completely lost. Those results suggested that a large group or a long chain on the phenyl ring at the C-4 position of the \(\beta\)-lactam was unfavorable for antiproliferative activity.

Because trifluoromethanesulfonyl moiety was an active group in some anticancer agents, it was often used as a promising scaffold for drug discovery. To complete the SAR study, the effects of hydrogen atom and a large group (e.g., –SO\(_2\)CF\(_3\)) as the \(\beta\)-lactam C-3 substituent were investigated (Region V). Changing the hydrogen atom at the C-3 position of the \(\beta\)-lactam to the trifluoromethanesulfonyl group resulted in inactive compounds, indicating that the hydrogen atom was critical for antiproliferative activity. The detailed structure–activity relationships of all the synthesized \(\beta\)-lactam-azide derivatives were summarized as Supplementary Fig. S2.

**Compound 28 induces G2/M arrest in cell cycle progression.** Due to the most potent antiproliferative activity against all selected tumor cells, compound 28 was chosen to further investigate its underlying biological mechanisms. As shown in Fig. 3, 28 induced cell cycle arrest at the G2/M phase in a concentration and time dependent manner. 28 treatment of MGC-803 cells at concentrations of 0, 0.1, 0.2 and 0.3 \(\mu\)M for 24 h resulted in 3.58%, 14.13%, 23.42% and 44.37% of G2/M populations, respectively (Fig. 3A), when MGC-803 cells were exposed to 0.1 \(\mu\)M 28 for 0, 12, 24, and 36 h, the percentages of MGC-803 cells at the G2/M phase were 5.77%, 12.63%, 23.02% and 44.59%, respectively (Fig. 3C).

**Compound 28 induces cell apoptosis by increasing the expression of BAX and decreasing the expression of Bcl-2 leading to activation of the caspase cascade.** We next evaluated whether 28 induces apoptosis in MGC-803 cells by flow cytometry analysis of propidium iodide (PI) and Annexin V stained cells. As shown in Fig. 4, 28 caused

---

**Table 1.** IC\(_{50}\) values (\(\mu\)M) of synthesized compounds. Cell lines were treated with compounds for 48 h. IC\(_{50}\) values were indicated as the mean ± SD (standard error) of at least three independent experiments.
cell apoptosis in a concentration-dependent manner. When MGC-803 cells were incubated with 28 at 0.1, 0.2, and 0.3 μM for 24 h, the percentages of early apoptotic cells were 12.4%, 40.5%, and 49.7%, respectively and those of late apoptotic cells 2.1%, 10.1%, and 9.4%, respectively (Fig. 4A). Bcl-2 family proteins were crucial components of mitochondrial stress-induced cellular apoptosis 44. Thus, the expression of apoptosis-related proteins was also determined. Western blotting analysis of 28 treated MGC-803 cells further revealed an increased protein expression of BAX and a decreased expression of Bcl-2, which was accompanied by increased expression of cleaved caspase-3, caspase-9 and PARP in a concentration-dependent manner (Fig. 4C).

Compound 28 induces tubulin destabilization targeting the colchicine site. As the microtubule system plays a vital role in the maintenance of cell shape and basic cellular functions, an immunofluorescence staining assay was performed to study whether compound 28 could disrupt the microtubule dynamics in living cells 45. 0.075 μM 28 moderately depolymerized interphase microtubules, whereas the depolymerization effect of 0.3 μM 28 is much stronger in MGC-803 cells (Fig. 5A).

The in vitro tubulin polymerization inhibitory activity of 28 was then evaluated. Purified and unpolymerized tubulin was incubated with 28 at indicated concentrations, and tubulin polymerization was measured by the method originally described by D. Bone et al.46. Derivative 28 inhibited in vitro polymerization of a concentration dependent manner (Fig. 5B), with an IC₅₀ value of 2.262 ± 0.017 μM.

In order to evaluate whether 28 directly binds to tubulin at the colchicine binding site, we carried out a competition assay with N,N′-ethylene-bis(iodoacetamide) (EBI) in MGC-803 cells as described in a previously published paper 47. EBI was an alkylating agent that cross-links the Cys239 and the Cys354 residues of β-tubulin involved in the colchicine-binding site, forming a EBI: β-tubulin adduct 48. The adduct was easily detectable by Western blot as a second immunoreactive β-tubulin band that migrated faster than β-tubulin itself 49. Preincubation of 28 (0.25 and 5 μM) dose-dependently prevented the formation of the EBI: β-tubulin adduct, resulting in the disappearance of the adduct band, which was consistent with the effect of colchicine (10 μM). Thus, the assay (Fig. 5C) indicated that 28 may directly bind to the colchicine-binding site of β-tubulin.

In continuation with our efforts to rationalize our experimental findings and investigate the potential binding site of the target compound with tubulin-microtubule system, molecular modeling studies were performed as described previously 50. Docking studies in Fig. 5D and E showed that 28 occupied the colchicine binding site of tubulin in agreement with the X-ray structure of tubulin cocrystallized with a colchicines derivative, N-deacetyl-N-(2-mercaptopropionyl)colchicine (DAMA-colchicine, PDB entry 1SA0) 51. Compound 28 formed...
hydrophobic interactions with the residues of Val318, Val315, Leu248, Leu255, Ile378, Ala316, Ala354. The azide group of phenyl ring at the C-4 position of 28 formed a hydrogen bond with the residue Val238. Importantly, the \(p\)-methoxy group of phenyl ring at the N-1 position of the \(\beta\)-lactam 28 formed a hydrogen bond with the residue Ala250, which could explain the importance of trimethoxyphenyl ring for its potent antiproliferative activity.

Compound 28 inhibits migration of MGC-803 cells by up-regulation of E-cadherin and ZO-1 expression and down-regulation of N-cadherin expression. The epithelial-mesenchymal transition (EMT) was an unique process for the phenotypic changes of tumor cells characterized by a transition from polarized rigid epithelial cells to migrant mesenchymal cells, thus conferring the ability of tumor invasion and metastasis\(^\text{52}\). EMT could suppress tubulin tyrosine ligase and promote microtubule stability\(^\text{53}\), resulting in tubulin detyrosination and the formation of microtentacles for supporting endothelial cell attachment\(^\text{54}\). In this study, we found that 28 could reverse the EMT progress (Fig. 6).

In a scarification test, compared to control, the distances of scratches after MGC-803 cells were treated with 28 obviously increased in a time-dependent and concentration-dependent manner (Fig. 6A). In a transwell test, the average numbers of migrated cells in fields of control, 0.1 and 0.2 \(\mu\)M 28 treated MGC-803 cells were 29.4, 22.4 and 16.6, respectively (Fig. 6B and C). Based on the results from these tests, we next examined the protein expression of EMT-related makers such as E-cadherin, N-cadherin, ZO-1 and Vimentin\(^\text{55}\). The results showed that the expression of E-cadherin and ZO-1 was up-regulated and that N-cadherence and vementin were down-regulated by 28 (Fig. 6D). This result suggests that 28 could inhibit the EMT process in tumor cells.

The in vivo antitumor effect of 28 in a xenograft model. To evaluate the potential antitumor effects of 28 in vivo, a MGC-803 xenograft model were established in nude mice by subcutaneously injecting MGC-803 cells at its logarithmic phase into the right flank of mice\(^\text{56}\). Tumor bearing mice were then randomly assigned to five groups (control, 100 mg/kg CA-4P, 25, 50, 100 mg/kg 28) with 10 mice per group. Then, the mice were gavaged with saline (control), CA-4P and different concentrations of 28 in saline solution daily. The results in Fig. 7 showed that 100 mg/kg 28 caused a considerable suppression of tumor growth. At the end of the observation period, mean tumor volumes of control, CA-4P, 25, 50, and 100 mg/kg 28 groups were 1665.98 ± 568.36 mm\(^3\), 642.61 ± 449.92 mm\(^3\), 788.18 ± 435.92 mm\(^3\), 1125.93 ± 668.25 mm\(^3\) and 1273.88 ± 513.69 mm\(^3\), respectively.
The average tumor weights of control, CA-4P, 25, 50, and 100 mg/kg 28 groups were 1.23 ± 0.28 g, 0.45 ± 0.22 g (inhibitory rate: 63.27%), 0.53 ± 0.20 g (inhibitory rate: 59.34%), 0.85 ± 0.32 g (inhibitory rate: 30.78%), and 1.09 ± 0.31 g (inhibitory rate: 10.99%), respectively. The antitumor activity of 28 in vivo was similar to that of CA-4P. Importantly, the in vivo antitumor efficacy of 28 was achieved without causing any obvious loss of body weight (Fig. 7D). This result suggests that 28 has low toxicity toward mice.

Conclusion
A series of β-lactam-azide derivatives were designed, synthesized and evaluated for their antitumor activities. Among them, compound 28 possessed the most potent antiproliferative ability with an IC_{50} value of 0.106 μM against MGC-803 cells.

The first SAR for this β-lactam-azide scaffold was explored and highlighted as follows: (1) 3,4,5-trimethoxy phenyl ring at the N-1 position of the β-lactam was essential; (2) a hydrogen atom at the C-3...
position of the β-lactam was required for their potent antiproliferative activity, the large group (e.g.: –SO₂CF₃) at the same position diminished the inhibitory activity; and (3) the large group 1,2,3-triazole and long chain 1,2,3-triazole-dithiocarbamate on the phenyl ring at the C-4 position of the β-lactam completely diminished its antiproliferative activity.

Preliminary mode of action studies demonstrated that 28 halted cell cycle progression at the G2/M phase and induced apoptosis in MGC-803 cells via increased expression of BAX and decreased expression of Bcl-2. Immunofluorescence staining, in vitro tubulin polymerization inhibition and EBI competition assays, as well as

**Figure 6.** (A) Scarification test of 28 on MGC-803 cells. (B,C) Transwell test of 28 on MGC-803 cells. The data were presented as the mean ± SEM *P < 0.05, **P < 0.01. (D) MGC-803 cells were harvested and lysed for the detection of EMT-related markers after treated by different concentrations of 28.
molecular modeling study identified that compound 28 was a novel tubulin polymerization inhibitor probably by binding to the colchicine site of tubulin. For the first time, we reported that 28 inhibited cell migration by inhibiting the EMT process in gastric cancer cells. Importantly, 28 inhibited \textit{in vivo} tumor growth in a xenograft model without apparent toxicity. The antitumor efficacy of 28 in a xenograft model of MGC-803 cells is close to that of a FDA approved anti-tubulin drug, CA-4P. Taken together, compound 28 could be a lead candidate for its further development in treatment of gastric cancer.

**Experiment Section**

**Chemistry section.** (The detailed information is in Supplementary Information)

**Biological section.**  \textit{Cell-based cytotoxicity screening assay.} MGC-803 cell line was obtained from the Chinese Academy of Sciences (Shanghai, China). MCF-7 and A549 were from the National Cell Center, China. MGC-803 cells were cultured in DMEM culture medium (DMEM, Biological Industries, Kibbutz Beit Haemek, Israel). A549 and MCF-7 cells were cultured in 1640 medium (1640, Biological Industries, Kibbutz Beit Haemek, Israel). All medium were supplemented with 10% fetal bovine serum, 100 U/ml penicillin (North China Pharmaceutical group Co.), and 100 \(\mu\)g/ml streptomycin (North China Pharmaceutical group Co.). All cells were cultured at 37°C in a humidified incubator containing 5% CO\(_2\).

Synthesized analogues used in the study were dissolved in 100% cell culture grade DMSO and the final concentration of DMSO as <0.1% for testing on cancer cell lines. Cytotoxicity assays were performed on the human gastric carcinoma cell line MGC-803, the human mammary carcinoma cell line MCF-7, the human lung carcinoma cell line A549. Cells (3500–5000/well) were seeded into 96-well plates in 100 \(\mu\)L of culture medium. The cells were treated in triplicate with a gradient concentration of testing compounds and incubated at 37°C, 5% CO\(_2\) for 48 h. For all cell lines, CCK-8 assay was performed to measure cytotoxic effects. The absorbance was measured using a microplate reader (BioTek Instrument, Inc. Vermont, USA) with a test wavelength of 450 nm. The absorbance levels were corrected against untreated control absorbance values. All experiments were performed in triplicate and SPSS17.0 was used for data analysis to obtain IC\(_{50}\) values.

Figure 7. The \textit{in vivo} antitumor activity of 28. After administered with control (saline), CA-4P, 25, 50, and 100 mg/kg 28 for 21 days, the mice were sacrificed, and the tumors were weighed. (A,B) The images of euthanized mice and excised tumors. (C) Tumor volumes of mice in each group. (D) Body weights of mice from each group at the end of the observation period. (E) The weights of excised tumors from each group. The data were presented as the mean \(\pm\) SEM *\(P<0.05\), **\(P<0.01\), significantly different compared with the control by test.
AutoDock 4.0 program equipped with ADT was used to perform the automated molecular docking. A total of 60 possible binding conformations were generated and grouped into clusters based on a 1.0 Å cluster tolerance. The docking models were analyzed and represented using ADT.

Cell cycle analysis by flow cytometry. MGC-803 cells were incubated in the absence and presence of 28. Subsequently, the cells were fixed with 70% alcohol in PBS. The fixed cells were incubated with RNase (1 µg/mL) propidium iodide (50 µg/mL) for 2 h. Flow cytometry analysis was performed using BD FACS (Becton Dickinson, San Jose, CA, USA).

Analysis of apoptosis. An Annexin V-FITC/PI kit (KeyGEN BioTECH, Nanjing, China) was used to detect apoptosis. Cells were seeded in 6-well plates and treated with 0, 0.1, 0.2 and 0.3 µM of 28 for 24 h. Then MGC-803 cells were collected and suspended in binding buffer containing Annexin V-FITC (0.5 mg/mL) and PI (0.5 mg/mL) and incubated in dark for 20 min and analyzed by flow cytometry (Becton, Dickinson and Company, NJ). The apoptosis related proteins of western blot analysis were conducted according to our previously reported method.

Immunostaining and microscopy. Cell climbing slices were sterilized and placed on the bottom of a 24-well plate for 24 h before MGC-803 cells were incubated in DMSO, different concentrations of 28 or CA-4P solutions were added. The next day the cell climbing slices were fixed by 4% paraformaldehyde for 15 min after washed by PBS for 3 times. 0.5% Triton-X-100 was added and shaken for 20 min. 0.1% BSA was used to block for 30 min and then removed. The cell climbing slices were added α-tubulin antibody (1:100) and incubated overnight at 4°C in humid box. On the third day the humid box was taken out and balanced at 37°C for 30 min. The cell climbing slices were washed by PBST for 3 times for each of 3 minutes and coated with FITC antibody (1:500) in a dark place for 1 h at room temperature. DAPI was used to re-stained for 5 min and then removed. The cell climbing slices were sealing by an anti-fluorescence quenching agent and images collected by Laser scanning confocal microscope (Nikon, Japan).

In vitro tubulin polymerization assay. An amount of 5.6 mg/ml tubulin was resuspended in PEM buffer [80 mM PIPES (pH 6.9), 1 mM EGTA, 0.5 mM MgCl₂, 1 mM ATP, 10.2% (v/v) glycerol] and then was preincubated with compound 28 or vehicle DMSO on ice. The reaction was monitored by a spectrophotometer in absorbance at 340 nm at 37°C every 5 min. The final concentrations of 28 were listed as follows: 0, 1, 2, and 4 µM.

EBI competition assay. Six-well plates were seeded with MGC-803 cells at 5 × 10⁶ cells per well. Cells were first incubated with compound 28 (0.25 and 5 µM), or colchicine (10 µM) for 2 h and afterward treated with EBI (100 µM). After 2 h, the cells were harvested and cell extracts were prepared for Western blot analysis. 20 µg of proteins was subjected to gel electrophoresis using 10% polyacrylamide gels. The proteins were transferred onto PVDF membranes, then blocked by 5% nonfatmilk for 1 h, and subsequently incubated with anti-β-tubulin antibody for 16 h at 4°C. Next, the membranes were washed extensively and immunoreactive proteins were finally detected by chemiluminescence.

Molecular modeling Studies. We investigated the binding modes of the target compound by molecular docking study. For the receptor preparation, the PDB entry 1SA0 was downloaded from the Protein Data Bank (PDB). The 3D structures of the ligand 28 were generated using ChemBio3D Ultra 11.0 followed by energy minimization. AutoDock 4.0 program equipped with ADT was used to perform the automated molecular docking. A total of 60 possible binding conformations were generated and grouped into clusters based on a 1.0 Å cluster tolerance. The docking models were analyzed and represented using ADT.

Cell scarification assay. MGC-803 cells were seeded in 6-well plate until cells grew to confluence. Tips were used to make a scratch on cells. Control and 28 contained culture media without fetal bovine serum were added subsequently after 3 times of washing by PBS. Then the cells were cultured at 37°C in a humidified incubator containing 5% CO₂ and photos taken at 0, 16, 24 and 48 h, respectively.

Transwell cell migration assay. The test was performed in a transwell plate (Corning). MGC-803 cells were added to the upper chamber of a transwell plate. Control and different concentrations of 28 solutions were added to both upper and bottom chambers. Then the transwell plate was cultured at 37°C in a humidified incubator containing 5% CO₂ for 24 h. The next day, all contents in the upper chamber were removed and wiped by cotton buds. Alcohol was used to fix, and the crystal violet was used to stain the transwell for 30 min. After washed by PBS the cell chambers were observed and photos taken. The cell number of the migrated cells through the transwell was calculated by counting 5 visual fields of each group (P < 0.05). Statistical analyses were performed by SPSS 17.0.

In vivo anti-tumor activity. Animals were treated according to protocols established by the ethics committee of Zhengzhou University and the in vivo experiments were carried out in accordance with the approved guidelines and approved by the ethics committee of Zhengzhou University. BALB/c nude mice (18 g, aged 4–5 weeks) were purchased from Human SJA Laboratory Animal Co. Ltd. (Hunan, China). Mice were subcutaneously implanted with MGC-803 cells (5 × 10⁶ cells per mouse) on the right flank of nude mice. Once tumor volumes reached to approximately 100 mm³, the mice were randomly divided into corresponding saline, CA-4P (100 mg/kg), 28 (100 mg/kg), 28 (50 mg/kg) and 28 (25 mg/kg) treatment groups (n = 10 mice for each group). The treatment groups received intragastric administration of CA-4P and CA-4P per day for a period of 21 days. Then, the mice were euthanized and tumors isolated and weighed. Their body weights were measured and tumor sizes determined by vernier caliper measurement every other day.

Statistical evaluation. Data were presented as means ± SD. Statistical analyses were performed by the analysis of variance (ANOVA). All statistical analyses were performed by SPSS 17.0.
References

1. Stanton, R. A. et al. Drugs That Target Dynamic Microtubules: A New Molecular Perspective. *Med. Res. Rev.* 31, 443–481 (2011).
2. Xie, S. et al. Microtubule-Binding Proteins as Promising Biomarkers of Paclitaxel Sensitivity in Cancer Chemotherapy. *Med. Res. Rev.* 36, 300–312 (2016).
3. Honore, S. et al. Understanding microtubule dynamics for improved cancer therapy. *Cell. Mol. Life Sci.* 62, 3039–3056 (2005).
4. Lu, Y. et al. An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. *Pharm. Res.* 29, 2943–2971 (2012).
5. Ravelli, R. B. G. et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature* **428**, 198–202 (2004).
6. Romagnoli, R. et al. Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-[(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole. *Sci. Rep.* 6, 26602 (2016).
7. Zhao, W. et al. Tubulin structure-based drug design for the development of novel 4S-sulfur-substituted podophyllum tubulin inhibitors with anti-tumor activity. *Sci. Rep.* 5, 10172 (2015).
8. Duan, Y.-T. et al. Design, Synthesis and Antitumor Activity of Novel Link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potential Antitubulin Agents. *Sci. Rep.* 6, 25387 (2016).
9. Yan, J. et al. Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo. *J. Med. Chem.* 59, 5264–5283 (2016).
10. Grosios, K. et al. *In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug*. *Br. J. Cancer.* **81**, 1318–1327 (1999).
11. Rustin, G. J. et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. *J. Clin. Oncol.* **21**, 2815–2822 (2003).
12. Mehta, P. D. et al. 2-Azetidinone-A new profile of various pharmacological activities. *Eur. J. Med. Chem.* 45, 5541–5560 (2010).
13. Arya, N. et al. The chemistry and biological potential of azetidin-2-ones. *Eur. J. Med. Chem.* 74, 619–656 (2014).
14. Geesala, R. et al. 2-Azetidinones: Synthesis and biological evaluation as potential anti-breast cancer agents. *Eur. J. Med. Chem.* **124**, 544–558 (2016).
15. Rajashekar Reddy, C. B. et al. HDAC and NF-kB mediated cytotoxicity induced by novel N-Chloro 3-lactams and benzoxazole derivatives. *Chem-Biot. Interact.* 246, 69–76 (2016).
16. Galletti, P. et al. Targeting integrins αvβ3 and α3β1 with new 1-lactam derivatives. *Eur. J. Med. Chem.* 83, 284–293 (2014).
17. Ojima, I. et al. Asymmetric synthesis of building blocks for peptides and peptidomimetics by means of the [small beta]-lactam synthon method. *Chem. Soc. Rev.* 26, 377–386 (1997).
18. Hodge, M. et al. Synthesis and bioactivity of a side chain bridged paclitaxel: A test of the T-Taxol conformation. *Bioorg. Med. Chem. Lett.* 19, 2884–2887 (2009).
19. O’Boyle, N. M. et al. beta-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand. *J. Med. Chem.* **57**, 9370–9382 (2014).
20. Greene, T. F. et al. Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylatedzietidin-2-ones as Tubulin-Targeting Antitumor Agents. *J. Med. Chem.* 59, 90–113 (2016).
21. Tanabe, K. et al. Reductive activation of 3-fluorooxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation. *Bioorg. Med. Chem. Lett.* 22, 1682–1685 (2012).
22. Nicolau, N. et al. Azides Derived from Colchicine and their Use in Library Synthesis: a Practical Entry to New Bioactive Derivatives of an Old Natural Drug. *ChemMedChem* 5, 661–665 (2010).
23. Da Cruz, E. H. G. et al. Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights. *Eur. J. Med. Chem.* **122**, 1–16 (2016).
24. Thamilarasan, V. et al. Synthesis, molecular structure, biological properties and molecular docking studies on MnIII, CoII and ZnII complexes containing bipyrindine–azide ligands. *Eur. J. Med. Chem.* **89**, 266–278 (2015).
25. Lippeva, A. V. et al. Synthesis of 1H-1,2,3-triazole linked ary[(arylamidomethyl)-dihydrofurocoumarin hybrids and analysis of their cytotoxicity. *Eur. J. Med. Chem.* **100**, 119–128 (2015).
26. Legigan, T. et al. Synthesis and Antitumor Efficacy of a 3-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin. *J. Med. Chem.* 55, 4516–4520 (2012).
27. Fan, J. et al. Effect of Trans-2,3-Dimethoxyannamoyl Azide on Enhancing Antitumor Activity of Romidepsin on Human Bladder Cancer. *Clin. Cancer. Res.* 14, 1200–1207 (2008).
28. Pinney, K. G. et al. Synthesis and biological evaluation of ary azide derivatives of combretastatin a-4 as molecular probes for tubulin. *Bioorg. Med. Chem.* 8, 2417–2425 (2000).
29. Splestoener, T. J. et al. Synthesis and anti-tubulin activity of a 3′-(4-azidophenyl)-3′-dephenylpaclitaxel photoaffinity probe. *J. Med. Chem.* 47, 6459–6465 (2004).
30. Fu, D.-J. et al. Design and synthesis of formononetin-dithiocarbamate hybrids that inhibit growth and migration of PC-3 cells via MAPK/Wnt signaling pathways. *Eur. J. Med. Chem.* 127, 87–99 (2017).
31. Fu, D.-J. et al. Design, synthesis and antiproliferative activity studies of novel dithiocarbamate–chelate derivaives. *Bioorg. Med. Chem. Lett.* 26, 3918–3922 (2016).
32. Fu, D.-J. et al. Design, synthesis and antiproliferative activity studies of 1,2,3-triazole-chalcones. *MedChemComm* 7, 1664–1671 (2016).
33. Pitts, C. R. et al. Chemical synthesis of 3-lactams: asymmetric catalysis and other recent advances. *Cheminform* 45, 7930–7953 (2014).
34. Fu, D. J. et al. Synthesis of novel antiproliferative 1,2,3-triazole hybrids using the molecular hybridisation approach. *J. Chem. Res.* 40, 674–677 (2016).
35. Z. H. et al. Stereoselective Synthesis of 3-Lactam-triflones under Catalyst-Free Conditions. *Org. Lett.* 17, 5610–5613 (2015).
36. Brown, A. W. et al. Sydnoclycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4. *J. Med. Chem.* 59, 9473–9488 (2016).
37. Prinz, H. et al. N-Heterocyclic (4-Phenylpiperazin-1-yl)methanes Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization. *J. Med. Chem.* 60, 749–766 (2017).
38. Wang, J. et al. Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011). *Chem. Rev.* 114, 2432–2506 (2014).
39. Bauer, M. R. et al. Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs. *ACS. Chem. Biol.* 11, 2265–2274 (2016).
40. Sánchez-Roselló, M. et al. Diastereoselective Synthesis of 2-Phenyl-3-(trifluoromethyl)piperazines as Building Blocks for Drug Discovery. *J. Org. Chem.* 79, 5887–5894 (2014).
41. Goumont, R. et al. Super acids: the origin of the exceptional electron transmission capability of the SO₂CF₃ group in carbanion stabilization. *Org. Bio. Chem.* 1, 1741–1748 (2003).
42. Xiao, M. et al. Discovery of 4-Aryl-2-benzoyl-imidazoles as Tubulin Polymerization Inhibitor with Potent Antiproliferative Properties. *J. Med. Chem.* 56, 3318–3329 (2013).
43. Fu, D. J. et al. Design and synthesis of formononetin-dithiocarbamate hybrids that inhibit growth and migration of PC-3 cells via MAPK/Wnt signaling pathways. *Eur. J. Med. Chem.* **127**, 87 (2016).
44. Wei, M. C. et al. Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death. Science 292, 727 (2001).
45. Liu, Y.-N. et al. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site. J. Med. Chem. 59, 5341–5355 (2016).
46. Bonne, D. et al. 4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules. J. Bio. Chem. 260, 2819–2825 (1985).
47. Gagné-Boulet, M. et al. Stryl-N-phenyl-N’-(2-chloroethyl)ureas and styrlyphenylimidazolidin-2-ones as new potent microtubule-disrupting agents using combretastatin A-4 as model. Eur. J. Med. Chem. 100, 34–43 (2015).
48. Meegan, M. J. et al. Piperlongumine (pippline) and analogues: Antiproliferative microtubule-destabilising agents. Eur. J. Med. Chem. 125, 453–463 (2017).
49. Fortin, S. et al. Quick and Simple Detection Technique to Assess the Binding of Antimicrotubule Agents to the Colchicine-Binding Site. Biol. Proced. Online 12, 113–117 (2010).
50. Zhang, Z. et al. 3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b] pyrrole-9-carbonitrile (S1) Based Molecules as Potent, Dual Inhibitors of B-Cell Lymphoma 2 (Bcl-2) and Myeloid Cell Leukemia Sequence 1 (Mcl-1): Structure-Based Design and Structure-Activity Relationship Studies. J. Med. Chem. 54, 1101–1103 (2011).
51. Da, C. et al. How to Deal with Low-Resolution Target Structures: Using SAR, Ensemble Docking, Hydrophobic Analysis, and 3D-QSAR to Definitely Map the αβ-Tubulin Colchicine Site. J. Med. Chem. 56, 7382–7395 (2013).
52. Okamaya, A. et al. Identification of Tyrosine-Phosphorylated Proteins Upregulated during Epithelial-Mesenchymal Transition Induced with TGF-β. J. Proteome Res. 14, 4127–4136 (2015).
53. Segaoula, Z. et al. Synthesis and Biological Evaluation of N-[2-(4-Hydroxyphenylamino)-pyridin-3-yl]-4-methoxybenzenesulfonamide (ABT-751) Tricyclic Analogues as Antimitotic and Antivascular Agents with Potent in Vivo Antitumor Activity. J. Med. Chem. 59, 8422–8440 (2016).
54. Whipple, R. A. et al. Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtubulenes that Enhance Endothelial Engagement. Cancer Res. 70, 8127–8137 (2010).
55. Ma, L.-Y. et al. Design, Synthesis, and Structure–Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine–Thiourea Hybrids As Potent, Orally Active Antitumor Agents. J. Med. Chem. 58, 1705–1716 (2015).
56. Zheng, Y.-C. et al. Triazole-Dithiocarbamate Based Selective Lysine Specific Demethylase 1 (LSD1) Inactivators Inhibit Gastric Cancer Cell Growth, Invasion, and Migration. J. Med. Chem. 56, 8543–8560 (2013).

Acknowledgements
This work was supported by National Natural Science Foundation of China (Project no.81430085, 21372206, and 81172937 for H.-M.L, Ph.D; Project no.81273393 and 81673322 for Y.-B.Z), Educational Award from Ministry of Education (No.20134101130001 for H.-M.L), Dong-Jun Fu expresses thanks to the Outstanding PhD Training Program of Zhengzhou University for financial support.

Author Contributions
D.-J.F. designed this project, first synthesized these compounds, performed docking studies and X-ray experiments, analyzed the data and wrote this paper. L.F. performed most of the biology experiments, analyzed the data. J.-W.W. carried out the in vivo experiments. Y.-C.L., F.L., J.S., R.-W.M., and R.-H.Z. further synthesized the compounds based on established methods. Y.-Q.W., B.-K.H., X.-R.L, C.Z., S.-Y.Z., and L.Z. carried out part of the biology experiments. B.Z. performed part of X-ray experiments. Prof. H.-M.L, and Y.-B.Z analyzed the data, proofread this paper, and approved the submission.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-12912-4.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017